Literature DB >> 18310545

High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.

Moez Dungarwalla, Steve O Evans, Unell Riley, Daniel Catovsky, Clare E Dearden, Estella Matutes.   

Abstract

The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease. Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18310545     DOI： 10.3324/haematol.11903

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  20 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 2.  Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

Review 3.  Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.

Authors:  Clark W Distelhorst
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-25       Impact factor: 4.739

4.  Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.

Authors:  M W Harr; P F Caimi; K S McColl; F Zhong; S N Patel; P M Barr; C W Distelhorst
Journal:  Cell Death Differ       Date:  2010-03-19       Impact factor: 15.828

Review 5.  Chronic lymphocytic leukemia: treatment options for patients with refractory disease.

Authors:  Marina Motta; William G Wierda; Alessandra Ferrajoli
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

6.  Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression.

Authors:  Qing-Min Yao; Pei-Pei Li; Shu-Mei Liang; Kang Lu; Xiao-Juan Zhu; Yan-Xia Liu; Feng Zhang; Ting Yuan; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

7.  Treatment options for high-risk chronic lymphocytic leukaemia.

Authors:  Saman Hewamana; Claire Dearden
Journal:  Ther Adv Hematol       Date:  2011-06

8.  Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia.

Authors:  Andrea Schnaiter; Stephan Stilgenbauer
Journal:  Ther Adv Hematol       Date:  2011-08

9.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.

Authors:  J E Castro; D F James; J D Sandoval-Sus; S Jain; J Bole; L Rassenti; T J Kipps
Journal:  Leukemia       Date:  2009-08-20       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.